DE69738841D1 - Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie - Google Patents

Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie

Info

Publication number
DE69738841D1
DE69738841D1 DE69738841T DE69738841T DE69738841D1 DE 69738841 D1 DE69738841 D1 DE 69738841D1 DE 69738841 T DE69738841 T DE 69738841T DE 69738841 T DE69738841 T DE 69738841T DE 69738841 D1 DE69738841 D1 DE 69738841D1
Authority
DE
Germany
Prior art keywords
ligand
kappa
receptor activator
tnf superfamily
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738841T
Other languages
English (en)
Inventor
Dirk M Anderson
Laurent J Galibert
Eugene Maraskovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369779&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69738841(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE69738841D1 publication Critical patent/DE69738841D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69738841T 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie Expired - Lifetime DE69738841D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5997896P 1996-12-23 1996-12-23
US7718197P 1997-03-07 1997-03-07
US6467197P 1997-10-14 1997-10-14
PCT/US1997/023775 WO1998028426A2 (en) 1996-12-23 1997-12-22 Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily

Publications (1)

Publication Number Publication Date
DE69738841D1 true DE69738841D1 (de) 2008-08-28

Family

ID=27369779

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69740107T Expired - Lifetime DE69740107D1 (de) 1996-12-23 1997-12-22 Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
DE122010000048C Pending DE122010000048I1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE0951551T Pending DE951551T1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE69738841T Expired - Lifetime DE69738841D1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE69740107T Expired - Lifetime DE69740107D1 (de) 1996-12-23 1997-12-22 Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
DE122010000048C Pending DE122010000048I1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE0951551T Pending DE951551T1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie

Country Status (13)

Country Link
US (21) US6242213B1 (de)
EP (5) EP0951551B9 (de)
JP (7) JP4138013B2 (de)
AT (2) ATE401404T1 (de)
AU (2) AU713473B2 (de)
CA (1) CA2274987C (de)
DE (4) DE69740107D1 (de)
DK (1) DK0951551T4 (de)
ES (1) ES2144386T5 (de)
IL (1) IL130492A (de)
LU (1) LU91758I2 (de)
PT (1) PT951551E (de)
WO (2) WO1998028426A2 (de)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050060764A1 (en) * 2003-09-17 2005-03-17 Susan Gregory Mouse model for bone metabolism
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
EP0948530A2 (de) * 1996-12-13 1999-10-13 Schering Corporation Oberflächenantigene aus säugern mit strukturmotifen die charakteristisch für mitglieder der tnf liganden familie sind
EP0951551B9 (de) 1996-12-23 2012-12-26 Immunex Corporation Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
PT946725E (pt) * 1996-12-23 2011-04-20 Immunex Corp Activador do receptor de nf-kappa b, o receptor é membro da superfamília do receptor tnf
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
EP2336168A1 (de) * 1997-04-15 2011-06-22 Sankyo Company Limited Neues Protein und Methoe zur Herstellung
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
EP0974671B1 (de) 1997-09-24 2006-05-31 Sankyo Company, Limited Methode zur diagnose von abnormalem knochenstoffwechsel
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) * 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
DE69939822D1 (de) * 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
DK1114166T3 (da) * 1998-09-15 2005-08-01 Pharmexa As Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
IL145676A0 (en) 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
US6872806B1 (en) * 1999-06-25 2005-03-29 The Governors Of The University Of Alberta Polypeptide compositions formed using a coiled-coil template and methods of use
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
WO2001036637A1 (en) * 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1255558B1 (de) 2000-02-16 2006-06-14 Genentech, Inc. Anti-april antikörper und hybridomazellen
CA2400929C (en) † 2000-02-23 2011-05-31 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
ES2317924T3 (es) 2000-07-27 2009-05-01 Genentech, Inc. Administracion secuencial de cpt-11 y polipeptido apo-2l.
AU2001286586A1 (en) * 2000-08-18 2002-03-04 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
JP2004520011A (ja) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体
DE01973455T1 (de) * 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20040132971A1 (en) * 2001-02-09 2004-07-08 Haaning Jesper Mortensen Rank ligand-binding polypeptides
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
CA2441538A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
JP2005508284A (ja) * 2001-03-23 2005-03-31 ジェネンテック・インコーポレーテッド 免疫反応調節のためのｏｐｇリガンドの使用
US20040167072A1 (en) * 2001-05-11 2004-08-26 Aggarwal Bharat B. Inhibitors of receptor activator of NF-kappaB and uses thereof
CA2447431A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation Inhibitors of receptor activator of nf-kb and uses thereof
CA2447518A1 (en) * 2001-05-17 2002-11-21 Immunex Corporation Therapeutic use of rank antagonists
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002098362A2 (en) * 2001-06-06 2002-12-12 Immunex Corporation Use of rank antagonists to treat cancer
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
ATE433996T1 (de) 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
US20030050223A1 (en) * 2001-08-09 2003-03-13 Jonathan Lam Crystal forms and mutants of RANK ligand
EP2348043A1 (de) 2001-10-02 2011-07-27 Genentech, Inc. APO-2-Ligandvarianten und Verwendungen dafür
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
US20030100068A1 (en) * 2001-10-12 2003-05-29 Jonathan Lam RANKL mimics and uses thereof
CA2463478A1 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
CA2463649A1 (en) * 2001-10-15 2003-04-24 Barnes-Jewish Hospital Rankl mimics and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
EP1560843A4 (de) * 2002-01-04 2006-09-06 Xencor Inc Neue varianten von rankl-protein
US7381792B2 (en) * 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2003057856A2 (en) * 2002-01-04 2003-07-17 Xencor Dominant negative proteins and methods thereof
WO2003080671A1 (en) * 2002-03-21 2003-10-02 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20060141561A1 (en) 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1578305A4 (de) * 2002-12-10 2008-08-27 Schering Plough Ltd Hunde-rankl und herstellungs- und anwendungsverfahren dafür
EP1582589B1 (de) * 2003-01-10 2010-03-24 Protein Crystal Co., Ltd. Proteinkomplex, verfahren zu dessen herstellung und verwendung davon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7700574B2 (en) * 2003-09-17 2010-04-20 Isis Pharmaceuticals, Inc. Modulation of RANKL expression
US7252833B2 (en) * 2003-11-18 2007-08-07 Skeletal Kinetics, Llc Calcium phosphate cements comprising an osteoclastogenic agent
WO2005063170A2 (en) * 2003-12-29 2005-07-14 Toudai Tlo, Ltd. Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006014899A2 (en) 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
EP2336177A1 (de) 2004-08-04 2011-06-22 Amgen, Inc DKK-1 Antikörper
CN101035912A (zh) 2004-08-06 2007-09-12 健泰科生物技术公司 使用生物标志的测定法和方法
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2007006602A (es) * 2004-12-02 2007-12-10 Domantis Ltd Peptidos de dominio plad con vida media en suero aumentada debido a conjugacion con anticuerpos de dominio.
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
ZA200800969B (en) 2005-08-16 2009-08-26 Genentech Inc Apoptosis sensitivity to APO2L/TRAIL by testing for GalNac-T14 expression in cells/tissues
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
EP1854458A1 (de) * 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Verwendung einer Verbindung mit RANKL Aktivität
CA2651597C (en) 2006-05-12 2013-02-05 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
WO2008044378A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Réactif contenant une protéine fusionnée de rankl soluble avec un marqueur d'épitope
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008150025A1 (ja) 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. 新しい骨量増加薬
JP5237366B2 (ja) * 2007-06-20 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 炎症性関節疾患に対する抗ｉｌ−１７ａ治療のための関節破壊のバイオマーカー
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
KR100911852B1 (ko) 2007-11-26 2009-08-11 고려대학교 산학협력단 유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
WO2009105934A1 (zh) * 2008-02-27 2009-09-03 上海先导药业有限公司 抗人rankl单克隆抗体
CL2009001735A1 (es) 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
US8657662B2 (en) 2008-09-04 2014-02-25 Patent Investment & Licensing Company Gaming device having variable speed of play
EP2343087B1 (de) 2008-09-30 2018-07-18 Oriental Yeast Co., Ltd. Neuartiger induktor für chondrozytenproliferation und differenzierungs
CN101712964B (zh) * 2008-10-08 2013-05-08 上海科新生物技术股份有限公司 抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
WO2010062904A2 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
EP2420515A4 (de) * 2009-04-16 2013-08-28 Univ Tokyo Diagnose und behandlung von krebs mit anti-tmprss11e-antikörper
KR101153393B1 (ko) * 2009-09-21 2012-06-07 고려대학교 산학협력단 점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EP2433644A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebstherapeutika
EP2434285A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebsdiagnose
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
JPWO2012133914A1 (ja) 2011-03-31 2014-07-28 オリエンタル酵母工業株式会社 Ｒａｎｋｌアンタゴニストを含む癌免疫増強剤
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
FR2980711A1 (fr) * 2011-10-03 2013-04-05 Centre Nat Rech Scient Modulation du systeme immunitaire et des cellules stromales via rank
CA2854372A1 (en) 2011-11-07 2013-05-16 Universite Laval Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
MX368513B (es) 2012-06-06 2019-10-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
EP2968498A4 (de) 2013-03-15 2016-09-07 Biogen Ma Inc Faktor-ix-polypeptidformulierungen
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
WO2015030701A1 (en) * 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Fully human antibodies against human rankl
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6550045B2 (ja) 2013-10-09 2019-07-24 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 乳がんに由来する骨の転移がんの予後診断および処置のための方法
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3143404B1 (de) 2014-05-16 2018-08-29 Amgen Inc. Verfahren zur bestimmung von th1- und th2- zellpopulationen
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
JP7019422B2 (ja) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
US10584174B2 (en) 2015-05-18 2020-03-10 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
EP3299382B1 (de) * 2015-05-20 2023-04-26 Osaka University Oligopeptid mit proinflammatorischer zytokinsekretionshemmender wirkung
EP4349410A3 (de) * 2016-01-05 2024-06-05 The Trustees Of Columbia University In The City Of New York Zusammensetzung zur verwendung bei der therapeutischen behandlung von krebs oder einem tumor
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
AU2017214277B2 (en) * 2016-02-01 2020-02-27 Eli Lilly And Company Parathyroid hormone – anti-RANKL antibody fusion compounds
CA3016894A1 (en) 2016-03-08 2017-09-14 Janssen Biotech, Inc. Gitr antibodies, methods, and uses
EP3458610B1 (de) 2016-05-25 2021-05-05 Inbiomotion S.L. Therapeutische behandlung von brustkrebs auf der basis des c-maf status
JP7246306B2 (ja) 2016-10-28 2023-03-27 イーライ リリー アンド カンパニー 抗ｒａｎｋｌ抗体およびその使用
KR102557321B1 (ko) 2017-01-05 2023-07-18 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
SG11202104900SA (en) 2018-11-20 2021-06-29 Univ Cornell Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023179791A1 (en) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Treatment of musculoskeletal disorders
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4710457A (en) 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
EP0192658A4 (de) 1984-07-30 1987-07-13 Salk Inst For Biological Studi Retrovirale gentransfervektoren.
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0273928B1 (de) * 1986-07-18 1997-01-08 The University Of Melbourne Aktives protein in humoraler hyperkalzemia, durch bösartigkeit verursacht
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
US6121002A (en) * 1990-12-26 2000-09-19 The Rowett Research Institute Method to detect bone and other connective tissue disorders in humans and animals
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
ES2198025T3 (es) * 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
PT639079E (pt) 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
DK0832229T3 (da) 1995-06-07 2004-05-03 Immunex Corp CD40L-mutein
JP4435304B2 (ja) * 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
JPH0997808A (ja) 1995-09-29 1997-04-08 Mitsumi Electric Co Ltd ダイボンディング装置
JPH09151434A (ja) 1995-11-24 1997-06-10 Tootetsu:Kk 角形蛇籠の変形防止枠及びその蛇籠の設置方法
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
PT873405E (pt) 1996-01-11 2005-01-31 Immunex Corp Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos
JPH09217897A (ja) 1996-02-14 1997-08-19 Hitachi Ltd Ｓｆ６貯蔵供給装置、その貯蔵方法及び供給方法
JPH09224803A (ja) 1996-02-21 1997-09-02 Nakajima Cafe Honsha:Kk 蓋付きコーヒーカップ
US5766223A (en) 1996-03-21 1998-06-16 Johnson; Deborah M. Child's teething device
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP0948530A2 (de) * 1996-12-13 1999-10-13 Schering Corporation Oberflächenantigene aus säugern mit strukturmotifen die charakteristisch für mitglieder der tnf liganden familie sind
WO1998028423A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
EP0951551B9 (de) 1996-12-23 2012-12-26 Immunex Corporation Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2336168A1 (de) 1997-04-15 2011-06-22 Sankyo Company Limited Neues Protein und Methoe zur Herstellung
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) * 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
US6252180B1 (en) * 1999-08-09 2001-06-26 Lucent Technologies Inc. Electromagnetic interference cover for a conduit and an electronic equipment chassis employing the same
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
HUP0104688A3 (en) 1999-09-03 2004-07-28 Amgen Inc Thousand Oaks Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
CA2400929C (en) 2000-02-23 2011-05-31 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
JP2004520011A (ja) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7157993B2 (en) 2003-09-30 2007-01-02 Rockwell Scientific Licensing, Llc 1:N MEM switch module

Also Published As

Publication number Publication date
US6838262B1 (en) 2005-01-04
WO1998028426A2 (en) 1998-07-02
EP2314695A3 (de) 2011-12-21
JP4242913B2 (ja) 2009-03-25
EP0951551B1 (de) 2008-07-16
AU5718498A (en) 1998-07-17
DE122010000048I1 (de) 2011-05-05
US7744886B2 (en) 2010-06-29
US8569456B2 (en) 2013-10-29
EP0946725B1 (de) 2011-01-26
EP0946725A2 (de) 1999-10-06
DE951551T1 (de) 2000-09-14
US20030175840A1 (en) 2003-09-18
US20090017033A1 (en) 2009-01-15
JP2010241823A (ja) 2010-10-28
JP2002509430A (ja) 2002-03-26
US6242213B1 (en) 2001-06-05
US20020169117A1 (en) 2002-11-14
DE69740107D1 (de) 2011-03-10
US6562948B2 (en) 2003-05-13
ES2144386T3 (es) 2009-01-16
US8153775B2 (en) 2012-04-10
US8715683B2 (en) 2014-05-06
AU5618098A (en) 1998-07-17
DK0951551T3 (da) 2008-09-01
US20020086826A1 (en) 2002-07-04
US7411050B2 (en) 2008-08-12
JP2007014339A (ja) 2007-01-25
JP4054354B2 (ja) 2008-02-27
US20080009014A1 (en) 2008-01-10
US6017729A (en) 2000-01-25
US20110200990A1 (en) 2011-08-18
US20130203682A1 (en) 2013-08-08
EP0951551B2 (de) 2012-08-08
LU91758I9 (de) 2019-01-02
US6419929B1 (en) 2002-07-16
ATE401404T1 (de) 2008-08-15
US20050003391A1 (en) 2005-01-06
CA2274987A1 (en) 1998-07-02
JP2009051862A (ja) 2009-03-12
ATE497001T1 (de) 2011-02-15
US20120178912A1 (en) 2012-07-12
EP2371962A2 (de) 2011-10-05
EP2371962A3 (de) 2011-12-21
WO1998028424A3 (en) 1998-09-11
CA2274987C (en) 2012-01-24
EP0951551A2 (de) 1999-10-27
DK0951551T4 (da) 2012-09-10
US20020081720A1 (en) 2002-06-27
AU713473B2 (en) 1999-12-02
US6528482B1 (en) 2003-03-04
US7932375B2 (en) 2011-04-26
JP4203105B2 (ja) 2008-12-24
US6537763B2 (en) 2003-03-25
AU713471B2 (en) 1999-12-02
US6649164B2 (en) 2003-11-18
US20140235832A1 (en) 2014-08-21
JP2008113656A (ja) 2008-05-22
US20110086033A1 (en) 2011-04-14
EP0951551B9 (de) 2012-12-26
US20120034690A1 (en) 2012-02-09
US6479635B1 (en) 2002-11-12
LU91758I2 (fr) 2011-01-24
WO1998028424A2 (en) 1998-07-02
ES2144386T5 (es) 2012-12-07
JP2002509431A (ja) 2002-03-26
IL130492A (en) 2007-09-20
JP4138013B2 (ja) 2008-08-20
ES2144386T1 (es) 2000-06-16
EP2003203A1 (de) 2008-12-17
JP5096527B2 (ja) 2012-12-12
AU713471C (en) 2002-04-18
US20020086827A1 (en) 2002-07-04
JP2008133302A (ja) 2008-06-12
US20140186887A1 (en) 2014-07-03
ES2144386T9 (es) 2013-02-18
US8333963B2 (en) 2012-12-18
US8377690B2 (en) 2013-02-19
EP2314695A2 (de) 2011-04-27
IL130492A0 (en) 2000-06-01
US6740522B2 (en) 2004-05-25
PT951551E (pt) 2008-10-28
US7262274B2 (en) 2007-08-28

Similar Documents

Publication Publication Date Title
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
ATE187982T1 (de) Cytokine antagoniste
DE69633617D1 (de) Il-17 receptor
DK0760857T3 (da) Receptor for onkostatin M
ATE114724T1 (de) Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente.
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
DE69032963T2 (de) (Modifiziertes) hydriertes Dien-Blockcopolymer und dieses enthaltende Zusammensetzung
DE69327720T2 (de) Endothelin rezeptor antagonisten
DE69331175T2 (de) Interleukin-2 Rezeptor Gamma-Kette
IT1228211B (it) Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento.
DE58909630D1 (de) Photopolymerisierbares Gemisch und dieses enthaltendes photopolymerisierbares Aufzeichnungsmaterial
FR2695475B1 (fr) Conductivimètre pour mesurer en régime transitoire la conductivité d'un matériau injectable ou non.
IL99501A0 (en) Interleukin 9 receptors,methods for the use thereof and pharmaceutical compositions containing the same
NO179550C (no) Tachykinin reseptorantagonister
DE58907320D1 (de) Bituminöse Masse und deren Verwendung.
IT8948295A0 (it) Procedimento ed apparecchio per la cernita di materiali particellari mediante attrito
IT1223336B (it) Composizione bituminosa e suo impiego nel settore dell'impermeabilizzazione
DE69003364D1 (de) Einrichtung zum Einfahren von Gewindeverbindungen für Rohrstränge durch Festschrauben und Losdrehen.
DE29507680U1 (de) Antirutschvorrichtung für Stiegenaufgänge mit verbessertem Aufbau der Grundplatte und des Antirutschstreifens
ES295315U (es) Dispositivo de anclaje a barandillas perfeccionado, para porta-jardineras y similares
IT8622736A0 (it) Antagonisti dell'aldosterone.
DK410789A (da) Indretning til sneplov

Legal Events

Date Code Title Description
8363 Opposition against the patent
R082 Change of representative

Ref document number: 951551

Country of ref document: EP

Representative=s name: DF-MP, 80333 MUENCHEN, DE

R102 Epo decision maintaining patent in amended form now final

Ref document number: 951551

Country of ref document: EP

Effective date: 20120808